VISEN Pharmaceuticals (HKG:2561)
Hong Kong · Delayed Price · Currency is HKD 19.04
-0.06 (-0.31%)
Sep 18, 2026, 4:08 PM HKT
VISEN Pharmaceuticals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Operating Revenue | 34.71 | 0.17 | - | - | - |
Other Revenue | -11.66 | -0.03 | 2.78 | -1.67 | -2.3 |
| 23.05 | 0.14 | 2.78 | -1.67 | -2.3 | |
Revenue Growth | - | -95.10% | - | - | - |
Cost of Revenue | 16.63 | 0.15 | - | - | - |
Gross Profit | 6.43 | -0.01 | 2.78 | -1.67 | -2.3 |
Selling, General & Admin | 155.65 | 146.33 | 86.43 | 79.94 | 177.45 |
Research & Development | 84.24 | 93.48 | 90.52 | 57.69 | 179.55 |
Operating Expenses | 239.89 | 239.81 | 176.96 | 137.63 | 357 |
Operating Income | -233.47 | -239.82 | -174.18 | -139.3 | -359.29 |
Interest Expense | -3.09 | -1.1 | -0.16 | -0.32 | -0.62 |
Interest & Investment Income | 11.78 | 11.78 | 6.77 | 11.15 | 5.57 |
Currency Exchange Gain (Loss) | -13.64 | -13.64 | 2.69 | 4.71 | 79.78 |
Other Non Operating Income (Expenses) | -1.08 | -10.64 | -17.37 | -16.28 | -14.3 |
EBT Excluding Unusual Items | -239.51 | -253.42 | -182.24 | -140.05 | -288.86 |
Gain (Loss) on Sale of Assets | - | - | - | -0.24 | -0.1 |
Other Unusual Items | - | - | - | -109.28 | - |
Pretax Income | -239.51 | -253.42 | -182.24 | -249.57 | -288.97 |
Net Income | -239.51 | -253.42 | -182.24 | -249.57 | -288.97 |
Net Income to Common | -239.51 | -253.42 | -182.24 | -249.57 | -288.97 |
Net Income Growth | - | - | - | - | - |
Shares Outstanding (Basic) | 108 | 104 | 94 | 94 | - |
Shares Outstanding (Diluted) | 108 | 104 | 94 | 94 | - |
Shares Change | 12.01% | 10.71% | - | - | - |
EPS (Basic) | -2.21 | -2.44 | -1.95 | -2.67 | - |
EPS (Diluted) | -2.21 | -2.44 | -1.95 | -2.67 | - |
EPS Growth | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 |
Free Cash Flow | -459.94 | -449.07 | -140.98 | -271.83 | -248.03 |
Free Cash Flow Per Share | -4.24 | -4.33 | -1.51 | -2.90 | - |
Gross Margin | 27.87% | -7.35% | 100.00% | - | - |
Operating Margin | -1012.82% | -176338.97% | -6272.16% | - | - |
Profit Margin | -1039.02% | -186339.71% | -6562.55% | - | - |
Free Cash Flow Margin | -1995.31% | -330200.00% | -5076.52% | - | - |
EBITDA | -232.85 | -239.42 | -172.95 | -137.79 | -357.55 |
D&A For EBITDA | 0.62 | 0.41 | 1.23 | 1.51 | 1.74 |
EBIT | -233.47 | -239.82 | -174.18 | -139.3 | -359.29 |